Mode
Text Size
Log in / Sign up

Branch retinal vein occlusion

Part of Embolism and Thrombosis

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for branch retinal vein occlusion

10 trials tracked for branch retinal vein occlusion: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 119 citations.

10Trials tracked
6Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 2 Phase 3 4 Phase 2 2 Other / NA 2
  1. Phase 3 Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Completed · 119 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion Completed · 101 cited
  3. Phase 4 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Completed · 29 cited
  4. Phase 4 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion Completed
  5. Phase 3 Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) Completed
  6. Phase 3 Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO) Completed
Show 4 more trials
  1. Phase 2 Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab Completed
  2. Phase 2 REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study Completed
  3. N/A Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Completed
  4. N/A Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Branch retinal vein occlusion: what the trials found

Several anti-VEGF agents have demonstrated efficacy in treating branch retinal vein occlusion (BRVO). Ranibizumab showed significant improvements in Best Corrected Visual Acuity (BCVA), with mean changes ranging from 16.18 to 74.3 letters depending on the study cohort [3, 6]. In one large trial, Ranibizumab resulted in a high percentage of patients achieving gains of $\geq$15 letters by month 6 3, while another trial showed 77% of patients gained $\geq$15 letters over 6 months 6.

Aflibercept demonstrated significant clinical improvements for BRVO. Patients treated with Aflibercept showed a mean BCVA increase of 18.4 1 and a statistically significant gain in the percentage of participants achieving $\geq$15 letters in BCVA at week 24 compared to placebo (p=0.0003) along with a significant reduction in central retinal thickness (CRT) 5.

Other interventions include pegaptanib sodium, which showed a mean change in BCVA of 14 and a reduction in macular thickening measured by OCT3 (-205) 2. Faricimab was evaluated for BRVO; while it showed improvements in BCVA over 24 weeks (ranging from 11.5 to 15.9), the difference between treatment arms at week 24 did not reach statistical significance (p=0.4978) 4.

Ranibizumab was also evaluated in a smaller cohort of 12 patients, confirming its use in this condition 8.

For the clinician treating this condition

  • Ranibizumab is established as an effective treatment for BRVO, with significant improvements in BCVA and high rates of gaining $\geq$15 letters [3, 6].
  • Aflibercept provides statistically significant improvements in both BCVA scores and reduction in central retinal thickness (CRT) at 24 weeks [1, 5].
  • While Faricimab shows positive trends in BCVA improvement over 24 weeks, current data does not show a statistically significant difference between treatment arms at the 24-week mark 4.

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Embolism and Thrombosis

Related studies from across the Embolism and Thrombosis family.

D-dimer shows moderate diagnostic potential for ruling out deep vein thrombosis after total joint arthroplasty
Emergency Medicine Meta-analysis
D-dimer shows moderate diagnostic potential for ruling out deep vein thrombosis after total joint arthroplasty D-dimer test helps rule out dangerous blood clots after joint replacement
This meta-analysis of 7,123 patients evaluated the diagnostic performance of D-dimer for screening deep vein thrombosis following total join…
A new analysis of over 7,000 patients finds D-dimer blood test is moderately useful for ruling out deep vein thrombosis after hip or knee re…
Ankle pump exercises plus anticoagulants reduce postoperative DVT risk
Neurology Meta-analysis
Ankle pump exercises plus anticoagulants reduce postoperative DVT risk Ankle Pump Exercises May Lower DVT Risk After Surgery
This meta-analysis found that adding ankle pump exercises to anticoagulant therapy significantly reduced the risk of postoperative deep vein…
Adding ankle pump exercises to standard blood thinner therapy may significantly lower the risk of dangerous blood clots after surgery.
Endovascular therapy reduces post-thrombotic syndrome severity by 2.0 points compared to standard care
Radiology & Imaging RCT
Endovascular therapy reduces post-thrombotic syndrome severity by 2.0 points compared to standard care Endovascular Therapy Improves Quality of Life for Post-Thrombotic Syndrome
This randomized controlled trial of 225 patients with moderate or severe post-thrombotic syndrome and iliac-vein obstruction found that endo…
A new trial shows that endovascular therapy can reduce the severity of post-thrombotic syndrome and improve daily quality of life.
Intravitreal ziv-aflibercept reduces central macular thickness and improves visual acuity in DME and RVO
Ophthalmology Meta-analysis
Intravitreal ziv-aflibercept reduces central macular thickness and improves visual acuity in DME and RVO Trial shows ziv-aflibercept improves vision in macular edema cases
This systematic review and meta-analysis of 5 RCTs and 8 observational studies found that intravitreal ziv-aflibercept significantly reduced…
A new eye treatment called ziv-aflibercept may help reduce swelling and improve vision for patients with specific types of macular edema.
Systematic review and meta-analysis of machine learning models for deep vein thrombosis prediction in hospitalized adults
Rheumatology Meta-analysis
Systematic review and meta-analysis of machine learning models for deep vein thrombosis prediction in hospitalized adults Machine learning models predict blood clots in hospitalized adults with high accuracy
This systematic review and meta-analysis synthesized evidence on machine learning-based prediction models for deep vein thrombosis in hospit…
A new analysis of 17 studies shows machine learning models can predict deep vein thrombosis in hospitalized patients with an accuracy score …
Meta-analysis finds modest PTS reduction with compression stockings after DVT
Rheumatology Meta-analysis
Meta-analysis finds modest PTS reduction with compression stockings after DVT Long-term stockings lower risk of post-thrombotic syndrome in deep vein thrombosis patients
This meta-analysis of 1,775 patients with deep vein thrombosis evaluated long-term graduated compression stockings. It found a modest reduct…
A large review found long-term compression stockings modestly reduce the risk of post-thrombotic syndrome in people with deep vein thrombosi…
FDA Approves Pavblu (aflibercept) for Neovascular AMD, RVO, DME, and DR
Ophthalmology FDA Approval
FDA Approves Pavblu (aflibercept) for Neovascular AMD, RVO, DME, and DR FDA approves Pavblu to treat several eye conditions that cause vision loss.
The FDA approved Pavblu (aflibercept) for neovascular AMD, macular edema following RVO, DME, and DR. It is a VEGF inhibitor administered by …
The FDA approved Pavblu (aflibercept) for wet age-related macular degeneration, macular edema, diabetic macular edema, and diabetic retinopa…
Systematic review and meta-analysis finds high prevalence of ocular manifestations in leukemia patients
Hematology Meta-analysis
Systematic review and meta-analysis finds high prevalence of ocular manifestations in leukemia patients Leukemia patients face eye risks that doctors must spot early now
This systematic review and meta-analysis of 1016 patients with leukemia found a 42% prevalence of overall ocular manifestations.
New data shows almost half of leukemia patients have eye issues, so regular eye checks are essential for better care
Meta-analysis finds education lowers DVT risk after orthopedic surgery
Primary Care & Family Medicine Meta-analysis
Meta-analysis finds education lowers DVT risk after orthopedic surgery Teaching patients about DVT cuts risk after orthopedic surgery
This meta-analysis of six studies in orthopedic surgery patients found that education-based interventions were associated with a significant…
A review of studies finds that educating patients about deep vein thrombosis after orthopedic surgery can significantly lower their risk of …
External validation of three DVT prediction models in 1,270 acute stroke patients
Cardiology Meta-analysis
External validation of three DVT prediction models in 1,270 acute stroke patients Three DVT prediction models showed varying accuracy in a single-center stroke study
This single-center spatial validation cohort study assessed three deep vein thrombosis (DVT) prediction models in 1,270 patients with acute …
The Lu Qiufang model outperformed others with 82.1% accuracy in predicting deep vein thrombosis among 1,270 acute stroke patients at a Shenz…
Retrospective study links systemic BP control to better visual outcomes with conbercept for RVO-related macular edema
Dermatology Cohort
Retrospective study links systemic BP control to better visual outcomes with conbercept for RVO-related macular edema Your Blood Pressure May Decide How Well Eye Injections Work
A retrospective cohort study of 76 hypertensive patients with macular edema secondary to retinal vein occlusion found that those with contro…
If you need eye injections for fluid swelling behind the retina, keeping your blood pressure in check could decide how much vision you get b…
Asthma associated with increased odds of venous thromboembolism, pulmonary embolism, and deep vein thrombosis in observational studies
Allergy & Immunology Meta-analysis
Asthma associated with increased odds of venous thromboembolism, pulmonary embolism, and deep vein thrombosis in observational studies Asthma Linked to Higher Risk of Blood Clots in Observational Data
This meta-analysis of observational studies involving patients with asthma found a statistically significant association between asthma and …
People with asthma face a 1.61 times higher risk of blood clots, with the danger of pulmonary embolism rising 2.41 times and deep vein throm…